Skip to content

Randomized Controlled Trial of Short-Term Spinal Cord Stimulation for Herpetic Neuralgia

Randomized Controlled Trial of Short-Term Spinal Cord Stimulation for Herpetic Neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119074
Enrollment
Unknown
Registered
2026-02-14
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?Zoster-associated neuralgia

Interventions

Short-term Spinal Cord Stimulation (st-SCS) Treatment Group:Administer short-term spinal cord stimulation to patients with herpes zoster-associated neuralgia. Operation: Implant a temporary spinal cor
simultaneously provide basic drug treatment (pregabalin, initial dose 75mg twice daily, adjusted according to pain tolerance).
Conventional Drug Combined with Stepwise Invasive Treatment Group:Administer conventional drug treatment combined with stepwise invasive treatment when necessary to patients with herpes zoster-associa
2. Nerve block (Step 1): If NRS score decreases by =5 after 2 nerve block treatments, perform CT-guided dorsal root ganglion pulsed radiofrequency treatment with parameters: temperature 42?, duration

Sponsors

?The First Affiliated Hospital of Anhui Medical University??
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for ZAN (disease duration <=3 months, including acute and subacute stages); 2.No history of opioid abuse; 3.Able to understand and complete self-assessment scales; 4.Voluntarily participates and signs informed consent.

Exclusion criteria

Exclusion criteria: 1.Pain-related sensory loss in the target area; 2.Spinal lesions or deformities precluding electrode implantation; 3.Presence of tumors or tuberculosis at puncture sites or within the spinal canal; 4.Active systemic infection or local infection at puncture site; 5.Severe coagulation dysfunction or ongoing anticoagulant therapy; 6.Major organ dysfunction or terminal cancer rendering surgery intolerable; 7.Intellectual or psychiatric disorders impairing comprehension of self-assessment scales; 8.Pregnancy/lactation or concurrent hormone therapy; 9.Allergy to local anesthetics/therapeutic agents or coexistence of other neuropathic pain conditions.

Design outcomes

Primary

MeasureTime frame
Pain relief response rate (>=50% reduction in NRS score at 4 weeks post-treatment);Incidence of postherpetic neuralgia (PHN);

Secondary

MeasureTime frame
Pain intensity (NRS score);Quality of life (SF-36 questionnaire score);Analgesic medication use (mean daily dose of pregabalin);

Countries

China

Contacts

Public ContactKe Penghui

?The First Affiliated Hospital of Anhui Medical University??

864040149@qq.com+86 186 5591 1729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026